Common gene polymorphisms in the metabolic folate and methylation pathway and the risk of acute lymphoblastic leukemia and non-Hodgkin's lymphoma in adults

Cancer Epidemiology Biomarkers and Prevention

Volumn 13, Issue 5, 2004, Pages 787-794

  Gemmati, Donato ^a   Ongaro, Alessia ^a   Scapoli, Gian L ^a   Della Porta, Matteo ^a   Tognazzo, Silvia ^a   Serino, Maria L ^a   Di Bona, Eros ^b   Rodeghiero, Francesco ^b   Gilli, Giuseppe ^c   Reverberi, Roberto ^c   Caruso, Angelo ^a   Pasello, Michela ^a   Pellati, Agnese ^a   De Mattei, Monica ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b SAN BORTOLO HOSPITAL   (Italy)

^c S ANNA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ADENINE; CYTOSINE; DNA; FOLIC ACID; GUANINE; METHIONINE; THYMINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AGED; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA DETERMINATION; DNA METHYLATION; DNA POLYMORPHISM; DNA SYNTHESIS; EVALUATION; FEMALE; FOLATE METABOLISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION;

5-METHYLTETRAHYDROFOLATE-HOMOCYSTEINE S-METHYLTRANSFERASE; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; BASE SEQUENCE; CASE-CONTROL STUDIES; COHORT STUDIES; CONFIDENCE INTERVALS; FEMALE; FERREDOXIN-NADP REDUCTASE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INCIDENCE; LEUKEMIA, LYMPHOCYTIC, ACUTE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROBABILITY; PROGNOSIS; RISK ASSESSMENT; SEX DISTRIBUTION;

EID: 2942608990     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Greaves MF. Etiology of acute leukemia. Lancet 1997;349:344-9.
2. Smith MT, Zhang L. Biomarkers of leukemia risk: benzene as a model. Environ Health Perspect 1998;106:937-46.
3. Kuppers R, Klein U, Hansmann ML, Rajyewsky K. Cellular origin of human B-cell lymphomas. N Engl J Med 1999;341:1520-9.
4. Vanesse GJ, Concannon P, Willerford DM. Regulated genomic instability and neoplasia in the lymphoid lineage. Blood 1999;94:3997-4010.
5. Zingg JM, Jones PA. Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis. Carcinogenesis 1997;18:869-82.
6. Blount BC, Mack MM, Wehr CM, et al. Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage. Proc Natl Acad Sci USA 1997;94:3290-5.
7. Shane B. Folate metabolism. In: Picciano MF, Sokstad ELR, Gregory JF, editors. Folic acid metabolism in health and disease. New York: Willey-Liss; 1990. p. 65-78.
8. Lucock M. Folic acid: nutritional biochemistry, molecular biology, and role in disease processes. Mol Genet Metab 2000;71:121-38.
9. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-3.
10. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998;64:169-72.
11. Dianov GL, Timchenko TV, Sinitsina OI, Kuzminov AV, Medvedev OA, Salganik RI. Repair of uracil residues closely spaced on the opposite strands of plasmid DNA results in double-strand break and deletion formation. Mol Gen Genet 1991;225:448-52.
12. Stern LL, Mason JB, Selhub J, Choi SW. Genomic DNA hypomethylation, a characteristic of most cancers, is present in peripheral leukocytes of individuals who are homozygous for the C677T polymorphism in the methylenetetrahydrofolate reductase gene. Cancer Epidemiol Biomarkers & Prev 2000;9:849-53.
13. Friso S, Choi SW, Girelli D, et al. A common mutation in the 5, 10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci USA 2002;99:5606-11.
14. Leclerc D, Campeau E, Goyette P, et al. A. Human methionine synthase: cDNA cloning and identification of mutations in patients of the cbIG complementation group of folate/cobalamin disorders. Hum Mol Genet 1996;5:1867-74.
15. Harmon DL, Shields DC, Woodside JV, et al. Methionine synthase D919G polymorphism is a significant but modest determinant of circulating homocysteine concentrations. Genet Epidemiol 1999;17:298-309.
16. Matsuo K, Suzuki R, Hamajima N, et al. Association between polymorphisms of folate- and methionine-metabolizing enzymes and susceptibility to malignant lymphoma. Blood 2001;97:3205-9.
17. van der Put NMJ, Gabreels F, Stevens EMB, et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 1998;62:1044-51.
18. van der Put NMJ, Steegers-Theunissen RPM, Frosst P, et al. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 1995;346:1070-1.
19. Lucock M, Daskalakis I, Hinkins M, Yates Z. An examination of polymorphic genes and folate metabolism in mothers affected by a spina bifida pregnancy. Mol Genet Metab 2001;73:322-32.
20. Gemmati D, Previati M, Serino ML, et al. Low folate levels and thermolabile methylenetetrahydrofolate reductase as primary determinant of mild hyperhomocystinemia in normal and thromboembolic subjects. Arterioscler Thromb Vasc Biol 1999;19:1761-7.
21. Gemmati D, Serino ML, Trivellato C, Fiorini S, Scapoli GL. C677T substitution in the methylenetetrahydrofolate reductase gene as a risk factor for venous thrombosis and arterial disease in selected patients. Haematologica 1999;84:824-8.
22. Szczeklik A, Sanak M, Jankowski M, et al. Mutation A1298C of methylenetetrahydrofolate reductase: risk for early coronary disease not associated with hyperhomocysteinemia. Am J Med Genet 2001;101:36-9.
23. Chen J, Stampfer MJ, Ma J, et al. Influence of a methionine synthase (D919G) polymorphism on plasma homocysteine and folate levels and relation to risk of myocardial infarction. Atherosclerosis 2001;154:667-72.
24. Brown CA, McKinney KQ, Kaufman JS, Gravel RA, Rozen R. A common polymorphism in methionine synthase reductase increases risk of premature coronary artery disease. J Cardiovasc Risk 2000;7:197-200.
25. Ma J, Stampfer MJ, Giovannucci E, et al. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res 1997;57:1098-102.
26. Slattery ML, Potter JD, Samowittz W, Schaffer D, Leppert M. Methylenetetrahydrofolate reductase, diet, and risk of colon cancer. Cancer Epidemiol Biomarkers & Prev 1999;8:513-8.
27. Shen H, Spitz MR, Wang LE, Hong WK, Wei Q. Polymorphisms of methylene-tetrahydrofolate reductase and risk of lung cancer: a case-control study. Cancer Epidemiol Biomarkers & Prev 2001;10:397-401.
28. Ma J, Stampfer MJ, Christensen B, et al. A polymorphism of the methionine synthase gene: association with plasma folate, vitamin B12, homocysteine, and colorectal cancer risk. Cancer Epidemiol Biomarkers & Prev 1999;8:825-9.
29. Skibola CF, Smith MT, Kane E, et al. Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci USA 1999;96:12810-5.
30. Franco RF, Simoes BP, Tone LG, Gabellini SM, Zago MA, Falcao RP. The methylenetetrahydrofolate reductase C677T gene polymorphism decreases the risk of childhood acute lymphocytic leukemia. Br J Haematol 2001;115:616-8.
31. Wiemels JL, Smith RN, Taylor GM, Eden OB, Alexander FE, Greaves MF. Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia. Proc Natl Acad Sci USA 2001;98:4004-9.
32. Skibola CF, Smith MT, Hubbard A, et al. Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia. Blood 2002;99:3786-91.
33. Gaughan DJ, Kluijtmans LAJ, Barbaux S, et al. The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations. Atherosclerosis 2001;157:451-6.
34. Ludwig ML, Matthews RG. Structure-based perspectives on B12-dependent enzymes. Annu Rev Biochem 1997;66:269-313.
35. O'Leary VB, Parle-McDermott A, Molloy AM, et al. MTRR and MTHFR polymorphism: link to Down syndrome? Am J Med Genet 2002;107:151-5.
36. Hobbs CA, Sherman SL, Yi P, et al. Polymorphisms in genes involved in folate metabolism as maternal risk factors for Down syndrome. Am J Hum Genet 2000;67:623-30.
37. Wilson A, Platt R, Wu Q, et al. A common variant in methionine synthase reductase combined with low cobalamin (vitamin B12) increases risk for spina bifida. Mol Genet Metab 1999;67:317-23.
38. Jacques PF, Bostom AG, Selhub J, et al. Effects of polymorphisms of methionine synthase and methionine synthase reductase on total plasma homocysteine in the NHLBI family heart study. Atherosclerosis 2003;166:49-55.
39. Melnyk S, Pogribna M, Miller BJ, Basnakian AG, Pogribny IP, James SJ. Uracil misincorporation, DNA strand breaks, and gene amplification are associated with tumorigenic cell transformation in folate deficient/repleted Chinese hamster ovary cells. Cancer Lett 1999;146:35-44.
40. Kunz BA. Mutagenesis and deoxyribonucleotide pool imbalance. Mutat Res 1988;200:133-47.
41. Tommerup N, Poulsen H, Brondum-Nielsen K. 5-Fluoro-2′-deoxyuridine induction of the fragile site on Xq28 associated with X linked mental retardation. J Med Genet 1981;18:374-6.
42. Baur AS, Shaw P, Burri N, Delacfetaz F, Bosman FT, Chaubert P. Frequent methylation silencing of p15(INK4b) (MTS2) and p16(INK4a) (MTS1) in B-cell and T-cell lymphomas. Blood 1999;94:1773-81.
43. Nakamura M, Sugita K, Inukai T, et al. P16/MTS1/INK4A gene is frequently inactivated by hypermethylation in childhood acute lymphoblastic leukemia with 11q23 translocation. Leukemia 1999;13:884-90.
44. Guo SX, Taki T, Ohnishi H, et al. Hypermethylation of p16 and p15 genes and RB protein expression in acute leukemia. Leukemia Res 2000;24:39-46.
45. Moller MB, Ino Y, Gerdes AM, Skjodt K, Louis DN, Pedersen NT. Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma. Leukemia 1999;13:453-9.
46. Bender CM, Pao MM, Jones PA. Inhibition of DNA methylation by 5-aza-2′-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res 1998;58:95-101.
47. Rampersaud GC, Kauwell GP, Bailey LB. Folate: a key to optimizing health and reducing disease risk in the elderly. J Am Coll Nutr 2003;22:1-8.